Teva, Mylan autoimmune news
Mylan said the U.S. Patent and Trademark Office issued a final rejection of Teva's application seeking a reissue of U.S. Patent No. 5,800,808, a process patent covering the biotech's Copaxone glatiramer for multiple sclerosis (MS). Last year, the U.S. Court of Appeals for the Federal Circuit invalidated the '808 patent, which was set to expire on Sept. 1, 2015.
Separately, Teva filed a motion asking the U.S. Supreme Court to stay pending judgment an appeals court ruling that will end exclusivity of Copaxone on May 24. Last month, the Supreme Court agreed to hear Teva's appeal of the appeals court ruling. A response to Teva's motion to stay is due April 14. In November, Supreme Court Justice John Roberts denied a request by Teva to stay the appeals court ruling (see BioCentury, July 29, 2013; Nov. 18, 2013 & April 7, 2014). ...